中國生物製藥(1177.HK)漲5% 獲鹽野義新冠口服藥獨家市場推廣權
格隆匯12月30日丨中國生物製藥(1177.HK)今早跳空高開5%報4.83港元,股價創今年7月20日以來新高。公司昨晚公吿,旗下子公司正大天晴藥業集團與平安鹽野義有限公司簽訂新型冠狀病毒感染治療藥物Ensitrelvir中國大陸地區的推廣協議,合作期限為5年。通過本次合作,中國生物製藥旗下正大天晴成為Ensitrelvir在中國內地的獨家市場推廣夥伴,將利用其在中國廣泛的銷售網絡,面向醫療機構進行該藥物的獨家推廣。Ensitrelvir是新型3CL蛋白酶抑制劑,由北海道大學與鹽野義製藥株式會社共同研發。3CL蛋白酶是新型冠狀病毒(SARS-CoV-2)病毒增殖所必需的一種酶,Ensitrelvir通過選擇性地抑制3CL蛋白酶從而抑制SARS-CoV-2的增殖。報道稱,該藥主要以輕症患者為對象,適用範圍覆蓋12歲以上人羣。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.